semaglutide cardiovascular risk Beyond obesity: Novo's SELECT re-defines management Oral Semaglutide and Cardiovascular Outcomes – semaglutide cardiovascular trial Wegovy shown

Felt great and even lost weight, inches, and firmed up my stomach

Importantly, the weight loss was attributed to enhanced satiety, fewer cravings, and reduced energy intake, which is consistent with earlier preclinical data

Visit us virtually Today

These include: Nausea Vomiting Diarrhoea Constipation Abdominal discomfort or bloating Reduced appetite (which may be intentional but can become excessive) These effects are typically most pronounced during the dose-escalation phase and tend to diminish as the body adjusts to the medication

Patients using semaglutide often report decreased hunger, shorter time to fullness, reduced cravings, heightened energy, and improved key health indicators, including blood pressure, cholesterol, and glucose levels

American Journal of Physiology-Endocrinology and Metabolism , 317(2), E360E373